TrialBritish journal of cancer2013

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

M Peeters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.